Evidence map›Paper›PMID 35044877›Full record

Trial reportHuman vaccines & immunotherapeutics2022

The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy.

Shiyi Chen, Yuping Zhao, Zhiyao Yang, Ying Li, Hongyuan Shi, Ting Zhao, Xiaolei Yang, Jing Li, Guoliang Li, Jianfeng Wang and 2 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shiyi ChenInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Yuping ZhaoInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Zhiyao YangFaculty of Science, The University of Adelaide, Adelaide, Australia.
Ying LiInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Hongyuan ShiInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Ting ZhaoInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Xiaolei YangInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Jing LiInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Guoliang LiInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Jianfeng WangLaboratory of respiratory virus vaccine, National Institutes for Food and Drug Control, Beijing, China.
Zhifang YingLaboratory of respiratory virus vaccine, National Institutes for Food and Drug Control, Beijing, China.
Jingsi YangInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the Global Polio Eradication Initiative has gradually implemented a global shift in polio immunization programs. Few studies cover polio immunization program impacts on the efficacy of other vaccines. This study investigated whether polio immunization programs affected hepatitis A (HepA) and hepatitis B (HepB) vaccination efficacy. Serum samples were collected from 968 infants before the first dose of polio vaccine, 28 days after completing primary polio immunization, and at 24 months old. Infants were classified into six polio immunization program groups: 1sIPV+2bOPV, 2sIPV+1bOPV, 2sIPV+1tOPV, 1cIPV+2bOPV, 2cIPV+1bOPV, and 2cIPV+1tOPV (sIPV: Sabin inactivated poliovirus vaccine; cIPV: Salk inactivated poliovirus vaccine; b, bivalent; t, trivalent; OPV, oral polio vaccine). No significant differences existed in antibody titers against HepA virus (anti-HAV) among the polio immunization program groups at any of the three time points (pre-first dose [

Indexed as

Hepatitis AHepatitis BPoliomyelitisPoliovirusChild, PreschoolHepatitis A AntibodiesHepatitis B AntibodiesHepatitis B VaccinesHumansImmunization ProgramsImmunization ScheduleInfantPoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralVaccinationVaccine EfficacyHepatitis A AntibodiesHepatitis B AntibodiesHepatitis B VaccinesPoliovirus Vaccine, InactivatedPoliovirus Vaccine, Oralhepatitis A virushepatitis B virusInactivated poliovirus vaccinesoral poliovirus vaccinessequential vaccination programvaccination

Identifiers

PMID35044877
PMCPMC8993082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.